ISTURISA
Total Payments
$844,163
Transactions
2,454
Doctors
1,095
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $712,121 | 586 | 349 |
| 2023 | $46,104 | 494 | 264 |
| 2022 | $85,937 | 1,374 | 676 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $542,809 | 76 | 64.3% |
| Honoraria | $168,182 | 51 | 19.9% |
| Consulting Fee | $55,884 | 24 | 6.6% |
| Food and Beverage | $46,312 | 2,258 | 5.5% |
| Travel and Lodging | $20,258 | 31 | 2.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,618 | 13 | 1.1% |
| Education | $1,100 | 1 | 0.1% |
Payments by Type
Research
$542,809
76 transactions
General
$301,354
2,378 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Block-and-replace Therapy with Osilodrostat and Concomitant Glucocorticoid Replacement | RECORDATI_RARE_DISEASES_INC. | $128,694 | 0 |
| Richard Auchus at Regents of the University of Michigan on A Block-and-replace Therapy with Osilodrostat and Concomitant Glucocorticoid Replacement | RECORDATI_RARE_DISEASES_INC. | $128,694 | 1 |
| Eliza Geer at Memorial Sloan Kettering Cancer Center on Pasireotide treatment for prolactinoma patients who have failed dopamine agonist therapy | RECORDATI_RARE_DISEASES_INC. | $100,625 | 1 |
| Detecting Mild Autonomous Cortisol Secretion in Patients with Adrenal Incidentaloma | RECORDATI_RARE_DISEASES_INC. | $38,192 | 0 |
| Ricardo Correa at Cleveland Clinic on Detecting Mild Autonomous Cortisol Secretion in Patients with Adrenal Incidentaloma | RECORDATI_RARE_DISEASES_INC. | $38,192 | 1 |
| Non-interventional Study on Osilodrostat in Patients With Endogenous Cushings Syndrome (LINC6) | RECORDATI_RARE_DISEASES_INC. | $33,300 | 0 |
| Adriana Ioachimescu at The Medical College of Wisconsin on Brain Alterations in Patients with Cushings Disease: A Prospective Longitudinal Study | RECORDATI_RARE_DISEASES_INC. | $25,111 | 1 |
| Incidence and Predictors of Severity of GWS after Curative Surgery in Patients with Endogenous CS | RECORDATI_RARE_DISEASES_INC. | $25,000 | 0 |
| Irina Bancos at Mayo Clinic on Incidence and Predictors of Severity of GWS after Curative Surgery in Patients with Endogenous CS | RECORDATI_RARE_DISEASES_INC. | $25,000 | 1 |
Top Doctors Receiving Payments for ISTURISA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Neelie Bean | — | Searcy, AR | $225,253 | 74 |
| , MD | Endocrinology, Diabetes & Metabolism | Ann Arbor, MI | $133,628 | 5 |
| , MD | Endocrinology, Diabetes & Metabolism | New York, NY | $100,625 | 1 |
| , MD, FACE | Endocrinology, Diabetes & Metabolism | Columbus, OH | $56,556 | 56 |
| , M.D | Endocrinology, Diabetes & Metabolism | East Providence, RI | $38,192 | 1 |
| , M.D., PH.D | Internal Medicine | Chicago, IL | $29,090 | 16 |
| , M.D | Endocrinology, Diabetes & Metabolism | Chapel Hill, NC | $26,744 | 14 |
| , MD | Endocrinology, Diabetes & Metabolism | Milwaukee, WI | $26,486 | 3 |
| , M.D | Internal Medicine | Rochester, MN | $25,000 | 1 |
| , D.O | Endocrinology, Diabetes & Metabolism | Dallas, TX | $15,271 | 6 |
| , MBCHB, MD, FRCP(UK) | Endocrinology, Diabetes & Metabolism | Phoenix, AZ | $15,053 | 9 |
| Catherine Zhang | Endocrinology, Diabetes & Metabolism | Milwaukee, WI | $13,911 | 4 |
| , M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $13,419 | 6 |
| , MD | Endocrinology, Diabetes & Metabolism | Nashville, TN | $12,268 | 9 |
| , M.D | Endocrinology, Diabetes & Metabolism | Wilmington, NC | $10,418 | 6 |
| , PA | Medical | Irvine, CA | $10,221 | 14 |
| , MD | Endocrinology, Diabetes & Metabolism | Portland, OR | $9,800 | 3 |
| , MD | Internal Medicine | Boston, MA | $8,175 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Saint Louis, MO | $7,316 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | Pittsburgh, PA | $6,897 | 13 |
| , MD | Internal Medicine | Charlottesville, VA | $3,965 | 1 |
| , M.D | Specialist | New York, NY | $3,384 | 6 |
| , M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $3,300 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Boston, MA | $2,600 | 1 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $1,750 | 1 |
Ad
Manufacturing Companies
- RECORDATI_RARE_DISEASES_INC. $844,163
Product Information
- Type Drug
- Total Payments $844,163
- Total Doctors 1,095
- Transactions 2,454
About ISTURISA
ISTURISA is a drug associated with $844,163 in payments to 1,095 healthcare providers, recorded across 2,454 transactions in the CMS Open Payments database. The primary manufacturer is RECORDATI_RARE_DISEASES_INC..
Payment data is available from 2022 to 2024. In 2024, $712,121 was paid across 586 transactions to 349 doctors.
The most common payment nature for ISTURISA is "Unspecified" ($542,809, 64.3% of total).
ISTURISA is associated with 9 research studies, including "A Block-and-replace Therapy with Osilodrostat and Concomitant Glucocorticoid Replacement" ($128,694).